{
    "clinical_study": {
        "@rank": "63847", 
        "acronym": "4P", 
        "arm_group": [
            {
                "arm_group_label": "Combined aspirin and multinutrient supplement", 
                "arm_group_type": "Experimental", 
                "description": "In a single capsule, the following will be combined: 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "5mg folic acid, cellulose filler"
            }
        ], 
        "brief_summary": {
            "textblock": "Hypertensive disorders of pregnancy (HDP) are with 50.000 deaths every year one of the major\n      causes of maternal mortality worldwide, especially in low and middle income countries. This\n      trial aims to determine whether a daily dose of combined low-dose aspirin, calcium, vitamin\n      D3, folic acid and vitamin B12 in pregnancy reduces the incidence of pregnancy-induced\n      hypertension in women at risk. Secondary and tertiary objectives include other maternal and\n      neonatal outcomes."
        }, 
        "brief_title": "Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia Trial", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pregnancy Induced Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Pre-Eclampsia", 
                "Hypertension, Pregnancy-Induced"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  <16 weeks of gestation and over 18 years of age,\n\n          -  Intention to have subsequent antenatal visits and delivery at the same clinic.\n\n          -  Can receive text messages by phone or through the phone of a proxy.\n\n          -  A moderate to high risk (>20%) of developing PIH\n\n        Exclusion Criteria:\n\n          -  Pre-existing hypertension or hypertension before 20 weeks gestation.\n\n          -  Likely non-compliance with the protocol in view of the treating physician\n\n          -  Comorbidity interfering with the protocol\n\n          -  Known contraindications to Investigational Product components"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "440", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007837", 
            "org_study_id": "GHS-ERC: 05/05/2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Combined aspirin and multinutrient supplement", 
                "description": "Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.", 
                "intervention_name": "Combined aspirin and multinutrient supplement", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Combined aspirin and multinutrient supplement", 
                    "Placebo"
                ], 
                "intervention_name": "Daily text reminder text messages", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aspirin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pregnancy induced hypertension", 
            "gestational hypertension", 
            "pre-eclampsia", 
            "preeclampsia", 
            "hypertensive disorders in pregnancy"
        ], 
        "lastchanged_date": "December 10, 2013", 
        "location": [
            {
                "contact": {
                    "email": "emmanuelsrofenyoh@gmail.com", 
                    "last_name": "Emmanuel K Srofenyoh, MBChB", 
                    "phone": "+233208118509"
                }, 
                "facility": {
                    "address": {
                        "city": "Accra", 
                        "country": "Ghana"
                    }, 
                    "name": "Ridge Regional Hospital"
                }, 
                "investigator": {
                    "last_name": "Emmanuel K Srofenyoh, MBChB", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "patrickfrimpong@hotmail.com", 
                    "last_name": "Patrick Frimpong, MBChB", 
                    "phone": "+233244270320"
                }, 
                "facility": {
                    "address": {
                        "city": "Accra", 
                        "country": "Ghana"
                    }, 
                    "name": "La General Hospital"
                }, 
                "investigator": {
                    "last_name": "Patrick Frimpong, MBChB", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Ghana"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia (4P) - a Randomised, Placebo-controlled, Double-blind Clinical Trial", 
        "overall_contact": {
            "email": "J.L.Browne@umcutrecht.nl", 
            "last_name": "Joyce L Browne, MD, MSc", 
            "phone": "+31649650071"
        }, 
        "overall_contact_backup": {
            "email": "D.E.Grobbee@umcutrecht.nl", 
            "last_name": "Diederick E Grobbee, MD, PhD", 
            "phone": "+31 (0)88 755 9358"
        }, 
        "overall_official": [
            {
                "affiliation": "UMC Utrecht", 
                "last_name": "Diederick E Grobbee, MD PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ghana Health Services", 
                "last_name": "Patrick Frimpong, MBbCh", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ghana Health Services", 
                "last_name": "Emmanuel K Srofenyoh, MBbCb", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Ghana: Food and Drug Authority", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Development of a de novo systolic blood pressure (SBP) of > 140 mmHg, diastolic blood pressure (DBP) of >90 mmHg, measured at least twice.", 
            "measure": "Development of pregnancy-induced hypertension (PIH) in pregnancy", 
            "safety_issue": "No", 
            "time_frame": "up to 2 days after delivery."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007837"
        }, 
        "responsible_party": {
            "investigator_affiliation": "UMC Utrecht", 
            "investigator_full_name": "Joyce L. Browne", 
            "investigator_title": "MD, MSc,PhD candidate", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "maternal death, preeclampsia, eclampsia, hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome, hemorrhage, caesarian section, other complications during pregnancy or delivery", 
                "measure": "Maternal/obstetric outcomes", 
                "safety_issue": "No", 
                "time_frame": "6-16 weeks gestation, 16-24 weeks gestation, 26-36 weeks gestation, delivery and first days after"
            }, 
            {
                "description": "preterm birth, Intra uterine death, stillbirth, neonatal mortality, congenital abnormality, Neonatal Intensive Care Unit (NICU) admission or pediatrician referral, birth weight, small for gestational age, apgar scores, other adverse effects. Infant outcomes: weight and height, health, occurrence of disease and general health status", 
                "measure": "Neonatal and infant outcomes", 
                "safety_issue": "No", 
                "time_frame": "6-16 weeks gestation, 16-24 weeks gestation, 26-36 weeks gestation, delivery and first days after"
            }, 
            {
                "description": "Number of patients with (severe) adverse events. Adverse events include any undesirable experience associated with the use of a medical product. Related to the product, bleeding incidences (including bruises), nausea, vomiting, will be explicitly reported.\nSevere adverse events are: death, life-threatening conditions, (prolonged) hospitalization, disability and permanent damage to mother or fetus, congenital abnormality, or other important (serious) medical events.", 
                "measure": "Number of participants with (severe) adverse events as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "UMC Utrecht", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Ghana Health Services", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Ghana", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "UMC Utrecht", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}